Autologous stem cell transplant poses slight second malignancy risk to MM patients
Autologous stem cell transplant (aHSCT) seems to increase the risk of haematologic second primary malignancy (SPM) among multiple myeloma (MM) patients, though the absolute estimates were small, a recent has found.
